📈 Join us for LIVE TRADING action all day long in the 📈
Market Master’s trading room
This morning’s scanner already: VRAX up 130%… FRGT up 82%… KITT up 32%
After a blistering hot day yesterday, I am so excited to hit the ground running this morning.
We had some really great ideas with my big personal win on QQQ, and we all saw the idea I shared pre-market with you make a 50% jump higher just a few hours after I told you about it.
Today, I have a fresh stock I want to share with you that also has incredible potential today.
Go to your favorite platform and pull up Tiziana Life Sciences (TLSA) right now, and I’ll tell you why it is so important right now.
The first thing I’ll say is, “Did you type in the right ticker?” LOL
I have typed in the ticker for “Tesla” so many times in my life, it is just natural habit to do that.
So, check it again. Look for TLSA!
If you’ve been following me for a while, you might recall I shared this idea with you a couple of months ago when the stock was trading around $.70.
While nothing goes in a straight line higher, TLSA has managed to continue the uptrend I pointed out and it is now just over $1.00.
While it might not seem like a lot at first glance, consider that’s around 40% higher now from where I first talked about it. Not the worst idea in the world, right?!
I always think that the longer an uptrend is in place, the more I start to trust it (though I always use good stop-loss rules)
You won’t find many uptrends better than TLSA over the last few weeks.
Just look at how it has managed to bang out a move over 120% higher from the lows it set several weeks ago…
You should always ask yourself, “Is this the top… or is this the spot where the trend continues higher?”
Personally, this is not a trend I would bet against right now.
When a super-strong stock like TLSA builds momentum above the 20-hour moving average (the yellow line on my chart above), that is one of the best spots I’ve found for a further breakout.
I just pointed out the same exact thing for QQQ on Tuesday, before I made the big win and it broke out yesterday.
I also showed this to you on the drone stock yesterday before it jumped 50% by lunchtime.
Every hour that TLSA holds above that 20-hour line, makes me more confident in the continuation of the breakout that has been happening.
Now, the converse is true too. If I started to see TLSA drop back under the yellow line for several hours, then I would probably go to the sidelines and wait for it to perk back up.
I am not a fan of buying stocks (even strong ones like TLSA) when they are under the 20-hour.
My best success has been when I was patient for a stock to build strength back above that level, which we clearly see is the case right now with TLSA.
I really think we are at a crucial point with this stock.
It is very important that you keep a close eye on TLSA today.
I will say that this can be a very volatile situation, so if decide to trade it, make sure you have a good game plan on where you would take profits or losses. Don’t try to make those decisions “in the heat of the battle.”
If a stock hits your profit target (mine is usually around 10%), then why not take it instead of hoping it will turn into 100% instead?
Same for me on the downside. I usually don’t want to lose more than 5-10% on a trade, so I keep those losses manageable when they happen.
I am expecting big things today for TLSA, so I hope I’m right!
Tiziana Life Sciences Ltd (TLSA) is a clinical-stage biopharmaceutical company developing breakthrough therapies for neuroinflammatory and neurodegenerative diseases with high unmet needs.
Its lead candidate, Foralumab, is a monoclonal antibody therapy that reduces inflammation by targeting a protein on T cells called CD3.
One of TLSA’s key innovations is to administer Foramulab intranasally, producing minimal toxicity while creating local T cells that more easily cross the blood-brain barrier.
The upshot is that Foramulab may help suppress the activation of the brain’s most prominent immune cells — called “microglial cells” — which are overactive in diseases such as multiple sclerosis and Alzheimer’s.
While there are other therapies that target CD3, Foralumab is the only CD3-targeting monoclonal antibody that is “fully human.” In theory, this should minimize adverse immune responses.
A similar anti-CD3 molecule that is only “humanized,” Teplizumab, was recently acquired by French pharma giant Sanofi for $2.9 billion.
Already, Foramulab has shown incredible promise at reducing microglial activation.
In April, TLSA presented data at the annual meeting of the American Academy of Neurology showing that nasal Foramulab “exhibited a reduction in microglial activation and disease stabilization in non-active secondary progressive multiple sclerosis [na-SPMS] patients … as observed through positron emission tomography (PET) imaging.”
Even more importantly, “clinically relevant improvements were observed in patient-reported outcomes, including stability … and improvements in fatigue levels.”
Dr. Tarun Singhal, an associate professor at Harvard Medical School, authored the study, noting that it “provides initial evidence that this fully human anti-CD3 has the potential to benefit this type of MS, which is the most difficult form to treat.”
Later that month, the company announced new data showing improvement in white matter “Z-scores” measured from PET images taken at 3 months in nasal foralumab-treated patients with na-SPMS.
In May, TLSA applied for Orphan Drug Designation for intranasal foralumab for the treatment of na-SPMS.
Based on population prevalence data, TLSA estimates there are 94,000 na-SPMS patients in the US and 155,000 in the EU.
But that form of multiple sclerosis isn’t the only potential indication for Foramulab. TLSA has also received Investigational New Drug clearance from the FDA for Foramulab as a treatment for Alzheimer’s, and it is also investigating the therapy for Long Covid, which is estimated to cost the US healthcare system almost $2.6 trillion.
TLSA’s pipeline
Dr. Matthew W. Davis, chief medical officer of TLSA, notes that, “We have now seen the potential of intranasal foralumab to dampen microglial activation in three major neuroinflammatory-related diseases, which creates significant optionality for exploring its benefits in some of the most important and burdensome medical conditions of our time.”
Lastly, the company just Tuesday revealed they had been invited to apply for a prestigious grant from the ALS Association which would support a clinical trial for intranasal foralumab to treat ALS, also known as Lou Gehrig’s disease.
Spend time right now doing your own research on the stock, and of course, always approach your trading in a responsible manner. Trading is very risky, and nothing is ever guaranteed, so never trade with more than you can afford to lose. Always have a well-thought-out game plan that takes your personal risk tolerance into consideration.
Bottom line: I think that TLSA is trading at a key level today, and it is very important to see where it goes from here. This could be the launchpad of the next breakout higher, though be prepared if it doesn’t work.
Put TLSA on top of your watchlist right away!
To Your Success,
Jeff Bishop
P.S. Make sure you join me and over 1000 traders in the Market Master’s trading room today for live trading signals and education. You can access it at no cost right now.
*Just so you know, what you’re reading is curated content for which we have received a monetary fee (detailed below) to create and distribute. Let’s be clear that investing can be quite the roller coaster as stock prices can have wild swings up and down, so consider those crucial risks before you ever consider trading anything we discuss. Make sure you check out our full disclosure down below for the details on how we were paid, the risks, and why these results aren’t what you’d call “typical.”
Just a quick heads up about this ad you’re reading—as we’ve said, even though we like the company referenced above, and all the facts we discussed above are true to the best of our knowledge, we are running a business here. To distribute this information and help offset the costs of maintaining our large digital audience, in advance of writing the content above, we received seventeen thousand five hundred dollars (cash) from Interactive Offers for advertising Tiziana Life Sciences Ltd for a one day marketing program on June 6, 2024. Before that, we were paid seventeen thousand five hundred dollars (cash) from Interactive Offers for advertising Tiziana Life Sciences Ltd for a one day marketing program on April 22, 2024 This amount was paid by someone else not connected to Tiziana Life Sciences Ltd. It might be obvious, but whoever paid for this might own shares and is likely looking to sell some or all of them at any time after we send out this information, which might affect the stock price. We may also buy or sell shares in the company at some point in the future, although neither RagingBull nor its owners own any shares of the company at this time. Also, keep in mind that due to the sheer size of our audience, if even a small percentage of people decide they want to buy this stock, it could potentially boost interest enough to hike up those share prices and cause a temporary spike, and the opposite is possible as our program ends, though that is not always the case.
Now, diving right into Tiziana Life Sciences Ltd might sound exciting. But remember, it’s like venturing into the wilderness—be aware that there’s exceptional risk involved in trading. This isn’t small potatoes we’re talking about; you could lose every dime you put in, so always carefully think about what you’re doing. That’s why they call this trading, after all. We’re shining a light on the good stuff about the company here, but it’s on you to do your homework, make your own calls, and determine a plan for your own trading, hopefully with the help of your professional 1nvestment advis0r.
Oh, that brings us to another crucial point—we’re not here to tell you (or even recommend) what you should do with your hard-earned money. We’re simply sharing our non-expert thoughts by highlighting some companies we like that could use some help telling their story to more people. We’re obviously biased in our writing. We’re not here to dig into anything that may be negative about the company; this is advertising, after all! Also, keep in mind that if we make some predictions about the future, these are technically known as “forward-L00king statements” under the securities acts, so take those with a grain of salt. As with all forecasts, they’re not set in stone, often wrong, and we certainly can’t know where the Company’s earnings, business, or share price will be tomorrow or a year from now.
Everything you read from us is all for your education, information, and possible entertainment. While we believe the info is reliable and accurate, we can’t wear a cape and guarantee it. Before you jump into anything, make sure to talk it over with a pro—someone you trust who’s licensed to give you real advice. To be clear,
Neither Raging Bull nor its owners, employees, or independent contractors are registered as a secur1ties br0ker-dealer, br0ker, 1nvestment advis0r (IA), or IA rep’s with the SEC, any state securities regulat0ry authority, or any self-regulat0ry organization.
So, that’s the scoop! If you’re intrigued and want to learn more about the companies we talk about, hit up the SEC’s website to dig into their filings and see the full picture.